3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
3
Prostatic Neoplasms
2
Neoplasms
2
Smoking
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hyperlipoproteinemia Type II
1
Hematologic Neoplasms
1
Hemangioma, Cavernous, Central Nervous System
1
Hearing Loss
1
Head and Neck Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Colitis, Ulcerative
1
Cardiotoxicity
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Paclitaxel
71
Bevacizumab
64
Carboplatin
56
pembrolizumab
46
olaparib
32
Gemcitabine
29
Specimen Handling
27
Cyclophosphamide
26
liposomal doxorubicin
24
Magnetic Resonance Spectroscopy
24
Cisplatin
22
niraparib
21
Taxes
19
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
13
Disulfides
13
Fulvestrant
12
Blood Specimen Collection
11
durvalumab
10
Oxaliplatin
10
mirvetuximab soravtansine
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Atorvastatin
×
1 year
×
Clear all
NCT05796973
2025-06-27
MOVES
Tampere University Hospital
Phase 3
Recruiting
240 enrolled